Vir Biotechnology, Inc. VIR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$125.7M-3.9% | -$42.92M+59.0% | -$163.14M+23.7% | -$110.96M+19.8% | -$120.97M-85.3% | ||
| $2.81M-2.0% | $2.9M+0.4% | $3M+3.5% | $2.92M-31.5% | $2.87M-36.5% | ||
| $12.09M-14.0% | $11.21M-29.3% | $11.36M-32.0% | $12.45M-43.8% | $14.06M-40.8% | ||
| -$4.23M-199% | $2.96M+253% | —— | $8.86M+406% | -$1.42M-293% | ||
| -$17.22M-196% | —— | -$14.16M— | -$23.47M-389% | $18.01M+160% | ||
| -$382K+92.4% | —— | -$4.22M— | -$879K+91.1% | -$5.06M-253% | ||
| -$2.27M-26.6% | -$2.32M+81.6% | -$1.79M+37.7% | -$1.46M+58.2% | -$1.8M+55.8% | ||
| -$132.39M-69.5% | -$25.88M+70.5% | -$167.57M+2.3% | -$120.22M-54.4% | -$78.12M+28.6% | ||
| $390K-76.1% | $348K-82.6% | $317K-88.5% | $2.54M+281% | $1.63M-13.0% | ||
| $158.37M-8.8% | $255.82M+59.0% | $264.45M+10.1% | $192.37M-29.1% | $173.69M-69.1% | ||
| $170.6M-43.5% | $342.93M+13.9% | $305.17M-15.6% | $251.32M-48.0% | $301.86M-49.1% | ||
| $11.84M-90.7% | $86.65M-38.4% | $40.45M-65.9% | $56.46M-73.3% | $126.82M+346% | ||
| $162.35M— | $1K-98.9% | $101K+42.3% | $1.25M+205% | $0-100% | ||
| $162.52M+27,078% | $1.04M-17.7% | $102K+229% | $2.05M-30.5% | $598K+293% | ||
| $41.97M-14.9% | —— | -$127.02M— | -$61.72M-145% | $49.3M+161% | ||
| -$394K+90.4% | -$1.55M+28.6% | -$1.32M-271% | -$2.52M+4.4% | -$4.09M-1,618% | ||
| $82K+1,267% | $132K+105% | —— | —— | $6K— | ||
| -$890K-186% | $0-100% | $560K-78.2% | $9.98M+234% | $1.03M-37.6% | ||
| -$17.22M-196% | —— | -$14.16M— | -$23.47M-389% | $18.01M+160% | ||
| -$2.27M-26.6% | -$2.32M+81.6% | -$1.79M+37.7% | -$1.46M+58.2% | -$1.8M+55.8% | ||
| -$657K+89.4% | $8.72M— | $2.79M+261% | $7.33M+821% | -$6.2M-7,309% | ||
| -$382K+92.4% | —— | -$4.22M— | -$879K+91.1% | -$5.06M-253% | ||
| $1.34M+19.4% | $1.33M+20.6% | $1.3M+5.4% | $1.24M-16.0% | $1.12M-22.5% | ||
| $170.6M-43.5% | $342.93M+13.9% | $305.17M-15.6% | $251.32M-48.0% | $301.86M-49.1% | ||
| $0-100% | —— | $37K+640% | $45K-88.1% | $281K-47.3% | ||
| $170K+103% | —— | -$1.34M— | —— | -$6.38M-208% | ||
| -$2.27M-26.6% | -$2.32M+81.6% | -$1.79M+37.7% | -$1.46M+58.2% | -$1.8M+55.8% | ||
| -$132.78M-66.5% | -$26.22M+70.7% | -$167.89M+3.7% | -$122.76M-56.4% | -$79.75M+28.3% | ||
| -$132.78M-66.5% | -$26.22M+70.7% | -$167.89M+3.7% | -$122.76M-56.4% | -$79.75M+28.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Vir Biotechnology, Inc.'s cash flow data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.